Free Trial
NASDAQ:DWTX

Dogwood Therapeutics Q4 2024 Earnings Report

Dogwood Therapeutics logo
$5.53 -0.13 (-2.30%)
Closing price 04:00 PM Eastern
Extended Trading
$5.45 -0.08 (-1.45%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dogwood Therapeutics EPS Results

Actual EPS
-$6.29
Consensus EPS
-$1.49
Beat/Miss
Missed by -$4.80
One Year Ago EPS
N/A

Dogwood Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dogwood Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 31, 2025
Conference Call Time
1:30PM ET

Upcoming Earnings

Dogwood Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Friday, May 9, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Dogwood Therapeutics Earnings Headlines

Dogwood receives Nasdaq confirmation of compliance
Get Your Bank Account “Fed Invasion” Ready with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Dogwood management to meet with Maxim
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX) is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

View Dogwood Therapeutics Profile

More Earnings Resources from MarketBeat